Antiphospholipid antibodies and stroke

Current Cardiology Reports

Volumn 6, Issue 2, 2004, Pages 130-134

  Tuhrim, Stanley ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; GLUCOCORTICOID; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PROTEIN; WARFARIN; CD18 ANTIGEN;

ANTIGEN ANTIBODY REACTION; ARTERY THROMBOSIS; CLINICAL TRIAL; COMPLEX FORMATION; HUMAN; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STROKE; VENOUS THROMBOEMBOLISM; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CEREBROVASCULAR ACCIDENT; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGENS, CD18; ANTIPHOSPHOLIPID SYNDROME; CEREBROVASCULAR ACCIDENT; HUMANS; RECURRENCE; THROMBOSIS;

EID: 2442663202     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0011-1     Document Type: Review

References (34)

1. Moore JE, Mohr CF: The incidence and etiologic background of chronic biologic false-positive reactions in serologic tests for syphilis. Ann Intern Med 1952, 37:1156-1161.
2. Moore JE, Lutz WB: The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors. J Chronic Dis 1955, 1:297-316.
3. Shapiro SS, Thiagarajan P: Lupus anticoagulants. Prog Hemost Thromb 1982, 6:263-285.
4. Bowie EJ, Thompson JH, Pascuzzi CA, et al.: Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963, 62:416-430.
5. Harris EN, Gharavi AE, Boey ML, et al.: Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983, 2:1211-1214.
6. Harris EN, Chan JK, Asherson RA, et al.: Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986, 146:2153-2156.
7. Hughes GR: The anticardiolipin syndrome. Clin Exp Rheumatol 1985, 3:285-286.
8. Harris EN, Hughes GR, Gharavi AE: Antiphospholipid antibodies: an elderly statesman dons new garments. J Rheumatol 1987, 13:208-213.
9. Galli M, Luciani D, Bertolini C, et al.: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832.
10. Campbell AL, Pierangeli SS, Wellhausen S, et al.: Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995, 73:529-534.
11. Tuhrim S, Rand JH, Wu X, et al.: Antiphosphatidyl serine antibodies are independently associated with ischemic stroke. Neurology 1999, 53:1523-1527.
12. Luong TH, Rand JH, Wu XX, et al.: Seasonal distribution of antiphospholipid antibodies. Stroke 2001, 32:1707-1711.
13. Rand JH: Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002, 90:29-37.
14. Atsumi T, Khamashta MA, Amengual O, et al.: Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 1998, 112:325-333.
15. Shibata S, Harpel PC, Gharavi A, et al.: Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994, 83:2532-2540.
16. Tuhrim S, Rand JH, Wu XX, et al.: Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999, 30:1561-1565.
17. Brey RL, Stallworth CL, McGlasson DL, et al.: Antiphospholipid antibodies and stroke in young women. Stroke 2002, 33:2396-2400.
18. Chakravarty KK, Byron MA, Webley M, et al.: Antibodies to cardiolipin in stroke: association with mortality and functional recovery in patients without systemic lupus erythematosus. Q J Med 1991, 79:397-405.
19. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993, 43:2069-2073.
20. Camerlingo M, Casto L, Censori B, et al.: Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand 1995, 92:69-71.
21. Kushner MJ: Prospective study of anticardiolipin antibodies in stroke. Stroke 1990, 21:295-298.
22. Hess DC, Krauss J, Adams RJ, et al.: Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology 1991, 41:525-528.
23. Ginsburg KS, Liang MH, Newcomer L, et al.: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117:997-1002.
24. Brey RL, Abbott RD, Curb JD, et al.: Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001, 32:1701-1706.
25. Vaarala O, Manttari M, Manninen V, et al.: Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995, 91:23-27.
26. Wu R, Nityanand S, Berglund L, et al.: Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997, 17:3159-3163.
27. Levine SR, Salowich-Palm L, Sawaya KL, et al.: IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997, 28:1660-1665.
28. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS). Neurology 1997, 48:91-94.
29. Levine SR: Anticardiolipin antibodies and recurrent thrombo-occlusive events: the Antiphospholipid Antibodies in Stroke Study (APASS) group [abstract]. Neurology 2002, Suppl 3:A257.
30. Tanne D, D'Olhaberriague L, Trivedi AM, et al.: Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 2002, 21:93-99.
31. Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
32. Tuhrim S, Godbold JH, Goldman ME, et al.: Can the lack of association between antiphospholipid antibodies and stroke recurrence be explained by their failure to persist [abstract]? Arterioscler Thromb Vasc Biol 2002, 22:375.
33. Khamashta MA, Cuadrado MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl Med 1995, 332:993-997.
34. Crowther MA, Ginsberg JS, Julian J, et al.: A comparison of intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133-1138.